| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 361.38 | 4.9% | 18.0% |
| Total Income | 363.82 | 4.9% | 18.1% |
| Expenditure | 274.69 | 2.8% | 8.9% |
| PBT | 111.22 | 40.0% | 99.2% |
| Net Profit | 79.76 | 39.1% | 90.2% |
| OPM | 50.31% | 6.87pp | 7.63pp |
| NPM | 21.92% | 5.38pp | 8.30pp |
| EPS | 0.72 | 24.1% | 63.6% |
Record PAT, but execution caution tempers the rally
Lemon Tree delivered its best-ever Q2 profit (₹79.8 Cr, +90% YoY) with operating margins hitting 50.3%. Yet management reaffirmed guidance rather than raising it. The call reveals why: corporate demand remains muted, and the growth pillars—Aurika, Omaxe, Fleur—face meaningful execution headwinds.
50.3%
includes 3.2% SAR/GST headwind
47.7%
+474 bps YoY; the clean underlying number
+90.2%
₹79.8 Cr vs ~₹42 Cr prior Q2
Reaffirmed
FY27 47%+, FY28 50%; not upgraded
On the surface, Lemon Tree posted its best-ever Q2: record PAT of ₹79.8 Cr (+90% YoY), operating margins at 50.3%, occupancy surging +633 basis points to 76.1%, and all guidance targets hit. It reads like a ramp story. But the earnings call tells a more cautious tale. Management reaffirmed guidance rather than raising it—a signal that execution risks on the company's three growth pillars (Fleur demerger, Omaxe partnership, Aurika brand scaling) are being taken seriously. Meanwhile, corporate demand, which was supposed to recover as geopolitical tensions eased, remains muted. That is the real tension: strong Q2 results sitting atop an uncertain execution roadmap and softening near-term demand for a key customer segment.
Where the profit came from
The 90% PAT growth outpaced the 18% revenue growth because of operational leverage. EBITDA grew 22% to ₹162.2 Cr as occupancy surged and the company achieved cost discipline. But the reported operating margin of 50.3% masks two headwinds. First, a 3.2% regulatory burden from retroactive GST demands and SAR provisions—real and recurring. Second, an exceptional ₹41 Cr non-cash credit from the Gurgaon hotel lease termination. Strip both, and the like-to-like operating margin is 47.7%, which validates the company's FY27 guidance ('above 47%') but also signals that underlying operational performance, while solid, is not inflated by one-time gains.
Best-ever second quarter, highest Q2 PAT
SupportedPAT ₹79.8 Cr (+90% YoY); prior Q2 baseline ~₹42 Cr
Like-to-like margins 47.7%, up 474 bps vs prior Q2
SupportedReported 50.3%; adjusted 47.7% excludes 3.2% SAR/GST headwind. Validates FY27 'above 47%' target.
Revenue grew 18% with balanced occupancy and ARR mix
Supported₹361.4 Cr delivered; ARR +8%, occupancy 76.1% (+633 bps). RevPAR +18% driven by both levers.
Corporate demand recovery underway post-geopolitical easing
OverstatedCorporate segment still muted; companies 'cutting down on discretionary travel.' IT sector hiring freezes ongoing. Management hedged H2 recovery to 55/45 retail-corporate split, with 'difficult to explain' H2 visibility.
Capex normalizing to ~1% of revenue from 2.25% in Q1
SupportedFY27 YTD capex ₹200 Cr on ~₹2,100 Cr run-rate (~9.5%); next 3.5 years ~₹3,000 Cr for new projects. Renovation dropping to 1.2% next year validates normalization target.
What changed on this call
Three material shifts from the prior quarterly narrative:
Corporate demand downgrade. Q1 call was optimistic on recovery; Q2 delivery shows corporate still muted, with IT sector hiring freezes and discretionary cuts offsetting leisure/MICE gains. Management now hedging H2 visibility ('difficult to explain how H2 plays out'). This is a narrative retreat.
Aurika Nehru Place delayed to CY31. 610-room flagship pushed from FY30 due to DDA tree-cutting approvals and environmental clearances. FY27 net keys guidance unchanged (2,000+), but timeline risk flagged. Management expects 'to make up half the time lost' post-approval.
Capex guidance reaffirmed, not upgraded. Total capex ₹200 Cr YTD (Bombay buyout, Shimla, Shillong). Normalization to ~1% from 2.25% Q1 is on track. Next 3.5 years ~₹3,000 Cr allocation (Omaxe, Aurika, acquisitions) highlights execution dependency. No new efficiency claim; just steady discipline.
The bull-bear ledger
Record PAT (+90% YoY) validates operational leverage in owned assets. Occupancy surge (+633 bps to 76.1%), ARR growth (+8%), and cost discipline yielding margin expansion. Keys portfolio RevPAR +29% YoY shows the brand is maturing and pricing power is real.
Like-to-like margin 47.7% confirms FY27 guidance; FY28 50% target is on the roadmap. Reported 50.3% includes one-time items; underlying performance is clean. Capex discipline (1% of revenue next year) supports margin progression.
Asset-light strategy (Omaxe 4,000 rooms, Fleur demerger 2,500 rooms) is structurally bullish. Fee-income leverage, no capex burden, Tier 2/3 growth without capital constraints. Fleur EBITDAR margin at 53% (+112 bps YoY) shows unit economics work. Target 70%+ post-demerger is ambitious but achievable.
Reported profit leans on regulatory one-time items and deflagging. 3.2% SAR/GST headwind, ₹41 Cr Gurgaon lease reversal (non-cash), 530 rooms deflagged in Q2 (450 ongoing compliance review). Expect headwinds to normalize, but deflagging trajectory is fuzzy ('minimal expected' vs. 'possible owners may correct').
Corporate demand still muted despite macro easing. IT sector hiring freezes, discretionary travel cuts persisting. Company targeting 55/45 retail-corporate split by H2 but hedging visibility. If corporate stays weak, occupancy gains plateau and ARR becomes the only growth lever.
Execution risks on three growth pillars are material and unproven at scale. Aurika Nehru Place delayed 6 months (DDA risk ongoing). Omaxe depends on 3–3.5 year construction timelines in Tier 2/3 cities (unproven). Fleur demerger contingent on NCLT approval (CY27 timeline at risk). Cascading delays compress the 'prove-it' window.
Guidance reaffirmed, not upgraded. FY27 margins 'above 47%' (hit on like-to-like basis); FY28 50% target held without increase. This signals confidence in execution—but also management's acknowledgement of risks ahead. No aspirational upside built into guidance.
Risks, ranked by how much they should concern a holder
Execution delays on growth pillars cascade
HIGHAurika Nehru Place (610 rooms) already 6 months behind schedule. Omaxe (4,000 rooms) depends on 3–3.5 year timelines. Fleur demerger (2,500 rooms) contingent on NCLT approval (CY27 target at risk). Delays compress the multi-year 'prove-it' window; FY28 50% margin target assumes on-schedule execution.
Corporate demand remains muted longer than expected
MEDIUM-HIGHIT sector hiring freezes and discretionary cuts are ongoing. Corporate segment target is 55/45 split by H2, but management hedged visibility ('difficult to explain'). If corporate stays weak through H2, occupancy plateaus at 76%+ and ARR becomes the only growth lever—capping revenue upside and delaying margin progression.
Regulatory and compliance headwinds persist or intensify
MEDIUM3.2% SAR/GST provision is real and recurring. Deflagging trajectory unclear (450 rooms ongoing, 'minimal expected' vs. 'possible owners may correct'). If compliance demands intensify or deflagging resumes, margins compress from the 47.7% clean level achieved this quarter.
Asset-light model execution depends entirely on partner performance
MEDIUMOmaxe partnership unproven at scale (first Greater Noida project 12–18 months away). Fleur success depends on independent operators hitting 70%+ EBITDAR margin post-demerger (ambitious). Fee income is a function of partner RevPAR, not controlled by LTH. Partner stumbles become LTH stumbles.
Supply oversupply in key metro markets compresses pricing
MEDIUM-LOWIHCL and ITC expanding aggressively in metros. Analyst flagged 'supply outpacing demand, RevPAR growth model at risk.' LTH counters with Tier 2/3 limited supply thesis and asset-light leverage—which is true—but if metros see pricing compression, blended RevPAR growth decelerates.
How the street is positioned
The stock is sending mixed signals. On the fundamental side, results are strong (record PAT, margin validation, occupancy gains). But on the positioning side, institutions are trimming exposure: FII ownership fell 119 basis points quarter-on-quarter to 18.26%, signaling net selling despite the Q2 beat. This divergence—strong earnings, weak flows—is worth parsing.
On the tape, the stock trades at ₹123.31, down 31.75% from its all-time high of ₹180.68, though it has recovered +23.79% from its 52-week low. It sits above key moving averages (SMA20 ₹114.55, SMA50 ₹110.37, SMA200 ₹113.16), and volume is increasing—suggesting accumulation despite the FII trim. RSI at 68.3 is neutral, not overbought, indicating room for upside if execution delivers.
The 31.75% drawdown from ATH is material. The stock traded at ₹180+ on the belief that Aurika, Omaxe, and Fleur would scale rapidly and re-rate the company to a higher growth multiple. The delays and corporate demand softness have reset that expectation. The current price (~₹123) reflects a more cautious path: steady margin expansion in owned assets, but slower growth pillars and near-term macro softness. FII trimming at these levels suggests they're no longer buying this thesis at current prices. This is a 'prove-it' valuation: execution on Aurika/Omaxe/Fleur will re-rate higher; stumbles will push lower. The stock is fair-priced for execution risk, not for execution upside.
The debate
What to watch next
1 · H2 FY27 corporate demand recovery signals
Company targeting 55/45 retail-corporate split by H2 (vs. current ~45–50% inferred). Management hedged visibility ('difficult to explain'). Watch for ARR growth ex-renovation and occupancy traction >77% as corporate bookings accelerate. If corporate stays tepid, occupancy plateaus and ARR becomes the only growth lever—capping revenue upside and validating the bear case.
2 · Fleur demerger approval and 2,500-room operationalization progress
Demerger targeted for CY27 (calendar 2027). This unlocks asset-light leverage (target 70%+ EBITDAR margin on 2,500-room portfolio). If NCLT approval slips to FY28, the catalyst delays. If approved on schedule and 2,500 rooms operationalize on time (FY30–FY31), fee-income acceleration should validate FY28 50% margin target for the blended entity.
3 · Aurika/Omaxe execution and first material opening
Watch: (a) DDA approval for Aurika Nehru Place (tree-cutting, environmental clearances); (b) Omaxe Greater Noida opening in 12–18 months and ARR achieved vs. ₹12,000 assumption; (c) speed of subsequent Omaxe projects. If timelines slip further or unit economics disappoint (ARR <₹10,000), the asset-light narrative re-rates lower and re-rating timeline extends.
Lemon Tree's Q2 is a solid, clean quarter: record PAT, margin expansion validated, occupancy surge, capex discipline all in place. But it is also a 'prove-it' quarter for a company that has reset its story from 'rapid Aurika/Omaxe growth' to 'steady margin expansion plus selective asset-light scaling.' Management's choice to maintain guidance rather than raise it reflects that realism.
The street's trim of FII exposure (down 119 bps despite strong results) tells you that institutions are pricing in execution risk on the growth pillars and macro softness on corporate demand. The 31.75% drawdown from ATH has reset expectations; the current price reflects a more cautious path.
For holders, the key number to track is the like-to-like operating margin (47.7% this quarter, 47%+ FY27 target, 50% FY28 goal). This reflects core operational health independent of regulatory one-time items. If LTH executes Aurika/Omaxe/Fleur on schedule and maintains margin momentum, re-rating to ₹140–150 is plausible. If execution stumbles or corporate demand stays weak through H2, the stock likely consolidates in the ₹115–130 range. The next two quarters are critical: H2 corporate recovery signals plus Fleur demerger progress updates will tell you which path LTH is on.
Best-ever Q2: 90% PAT growth, 50% OPM hit, but macro headwinds loom
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade A
Hit guidance on revenue (18% YoY), PAT (90% YoY), and margin (47.7% like-to-like vs 47%+ target). Reaffirmed FY28 50% margin target.
Optimistic
next 1–2 quarters
Optimistic
multi-year
LTH delivered a strong Q2 (90% PAT growth, 50% OPM) with margin expansion and occupancy momentum validated against guidance. However, corporate demand remains muted despite geopolitical uncertainty easing, and execution risks on key growth pillars (Aurika Nehru Place delays, Omaxe timelines, Fleur merger integration) warrant a cautious stance near-term. Asset-light strategy is bullish, but unproven at scale.
₹361.4 Cr
Revenue · +18% YoY₹79.8 Cr
Reported PAT · +90.2% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Best-ever second quarter with highest Q2 PAT
METPAT ₹79.8 Cr, up 90% YoY; prior Q2 baseline implied ~₹42 Cr
Like-to-like margins 47.7%, up 474 bps vs prior Q2
METReported OPM 50.3%; adjusted 47.7% excludes 3.2% SAR/GST impact
Revenue grew 18% YoY with balanced occupancy/ARR mix
METReported ₹363.8 Cr (vs delivered ₹361.4), ARR up 8%, occupancy 76.1% (+633 bps)
Occupancy surge driven by both leisure and corporate recovery
OVERSTATEDOccupancy 76.1% but corporate demand still muted due to geopolitical impact
Renovation capex normalizing to ~1% next year
METSpent Rs. 200 crore total CAPEX in FY27 (Bombay buyout, Shimla, etc.), baseline ₹2,000-2,100 Cr revenue run-rate
Earnings quality
What changed since the last call
Corporate demand narrative
DowngradeQ1 call was optimistic on corporate recovery post-West Asia conflict; Q2 delivery shows corporate still muted ('companies cutting down on discretionary travel'). Management now hedges: 'it is in the hands of God; we hope for 55/45 split between retail/corporate by H2.'
Aurika portfolio expansion roadmap
NeutralMaintained 2,000+ Keys net addition target for FY27. But Aurika Nehru Place (610 rooms) pushed from FY30 to CY31 due to DDA approvals. Shimla/Shillong/Varanasi on track. Net: timeline risk flagged but volume goal unchanged.
Capex guidance
MaintainedReaffirmed normalization to ~1% of revenue (from 2.25% in Q1). Total spent Rs. 200 Cr in FY27 YTD (Bombay buyout, land acquisitions, Shimla/Shillong). Next 3.5 years: ~₹3,000 Cr for new projects (Omaxe, Aurika pipeline).
Fleur EBITDAR margin assumption
NeutralFleur owned portfolio at 53% EBITDAR (up 112 bps YoY). Management expects blended EBITDA margin post-merger to reach 70%+ (from asset-light leverage). No change in target, but execution risk flagged ('depends on demerger timeline, construction challenges').
The Q&A
Analysts pressed hard on supply risk (Prachi Agarwal: IHCL/ITC expansion in luxury), Aurika unit economics (Achal Kumar: ₹8,900 ARR in Aurika Mumbai vs ₹25-30K at Marriott), capex/construction risk (Vaibbhav Muley: Bombay delays, environmental approvals). Management held firm: 'supply in Tier 2/3 is limited; our portfolio is in demand markets; renovations drive pricing power, not volume.' Tone was steady, not evasive.
FIT demand recovery signal — Karan Khanna, Ambit Capital
AnsweredWill stick to 55/45 guidance if geopolitical impact eases; corporate side still muted due to hiring freezes and IT sector slowdown; non-negotiated business picking up.
Hotel openings and deflags — Karan Khanna, Ambit Capital
AnsweredOpenings on track (gross 2,000 rooms); deflagging mostly Q1-Q2 due to compliance issues; expect no material deflagging in Q3-Q4. Gurgaon is force majeure (lease term), not systemic.
Aurika Nehru Place delays and ARR assumptions — Achal Kumar, HSBC
PartialDDA approvals delayed; expect construction to start in next 2-3 months. ARR of ₹12,000 is conservative; will achieve 12%-13% ROCE immediately at that level.
RevPAR split: ARR vs occupancy — Achal Kumar, HSBC
AnsweredBalanced. Q1 was occupancy-heavy (West Asia impact); Q2 more ARR-balanced (demand recovery, 8% ARR + occupancy gains). Long-term: occupancy and ARR will grow together.
F&B revenue growth divergence — Vaibbhav Muley, Haitong Securities
AnsweredFleur portfolio at 53% GOP margins; fees are ~40% function of EBITDA; GST and renovation caps fees this year; next year margins recover, fees accelerate.
ADR growth and GST impact — Vaibbhav Muley, Haitong Securities
AnsweredCurrently 50% of revenue above ₹7,500 (up from 48% prior year); gradual upside as renovations drive pricing. Focus is RevPAR, not ADR in isolation.
Gurgaon lease termination and exceptional items — Jinesh Joshi, PL Capital
AnsweredGurgaon: force majeure (fire removed banquet approval; lease terminated). Other deflagging (450 rooms) is ongoing due to compliance gaps, but management expects minimal future deflagging. Exceptional revenue (₹41 Cr) is non-cash accounting reversals.
Omaxe partnership terms and execution — Dikshi Jain, InCred Research
AnsweredAsset-light: Lemon Tree brands (Lemon Tree, Keys, Aurika). Two models: (a) Omaxe townships (Lucknow, Ghazabad, etc., 3-3.5 years); (b) PPP bus-station redevelopments (Tier 2/3, greenfield). ~400 rooms per property average. Greater Noida operational in next 12-18 months.
Fleur demerger timeline and 2,500-room operationalization — Dikshi Jain, InCred Research
PartialBy FY30-FY31 operational (brownfield/greenfield mix). Dependent on legal/technical diligence. 9 of 10 Omaxe properties are greenfield; expect 3-3.5 years to construct. One property (Greater Noida) next 12-18 months.
Supply-demand risk in luxury segment — Prachi Agarwal, Axis Capital
PartialSupply concentration in Tier 2/3 is limited; most growth is Tier 2/3, not luxury metros. Competitive but opportunity for us to increase network. Asset-light strategy allows us to grow without capital burden.
Loyalty program and repeat customer base — Rahul Majethia, Individual Investor
AnsweredCurrently 25% of business is loyalty; 45% is repeat guests (not loyalty members). Loyalty payout ~4% of revenue; breakage 30%-40%, actual consumption 60%-70%. Self-supporting internal system.
Franchise fee structures and escalation — Rahul Majethia, Individual Investor
AnsweredFees are revenue/EBITDA functions. No performance-linked escalators. Brand/distribution agreement; not operations control. 90%+ owners happy with performance; Lemon Tree is moral custodian.
Bandra land acquisition and ARR modeling — Achal Kumar, HSBC
AnsweredBandra-Kurla Complex is deep-demand market. Expected ARR ~₹12,000 at start; 12%-13% immediate ROCE. Comparable to other high-cost markets; will serve BKC clients.
Airline traffic divergence vs hotel demand — Sameet Sinha, Macquarie
AnsweredAirline data is proxy for FIT, not corporate. Corporate demand from internal hiring freezes (IT sector) and discretionary cuts. Retail and MICE recovering. Middle market is demand driver.
CAPEX guidance and renovation spend — Vaibbhav Muley, Haitong Securities
Answered60-65% renovation (OPEX), 35-40% capex (asset/land). Next 3.5 years: ~₹3,000 Cr total for new projects (Omaxe, Aurika, acquisitions). Renovation dropping to 1.2% of revenue next year from 2.25% in Q1.
Asset-light EBITDA margin trajectory — Zahra Patel, Solidarity Advisors
AnsweredYes. Hotels signed 3 years ago will ramp. Operating expenses at ₹100 Cr baseline; fee income targeting ₹500 Cr (₹400 Cr EBITDA, 80% flow-through). Expenses rise 4% annually; fees grow with volume.
Guidance
FY27: Double-digit growth achieved (18% YoY Q2 baseline)
HighQ2 at +18%; prior guidance 'Q2 onwards double-digit growth' confirmed. Full-year trajectory on track if H2 matches H1 momentum.
FY28: Capex normalized to ~1% of revenue from 2.25% in Q1
HighTotal FY27 capex ₹200 Cr (Rs. 2,100-2,200 Cr run-rate). Renovation dropping to 1.2% next year. Next 3.5 years ~₹3,000 Cr for new projects.
FY27 margins above 47% (maintained from prior call)
HighQ2 delivered 47.7% like-to-like (adjusted for SAR/GST 3.2% headwind). On track. Reported margin 44.6%, but on-track basis 47%+ achieved.
FY28 targeting 50% EBITDA margin (reaffirmed from prior call)
MediumFleur asset-light model targeting 70%+ EBITDA margin; Lemon Tree standalone margin expansion likely from renovation completion and operating leverage. No change vs prior, but achievable.
Total capex FY27-FY30: ~₹3,000 Cr for new projects (Omaxe, Aurika, acquisitions)
MediumDependent on acquisition closures (Omaxe, Warburg Pincus Fleur investment), construction timelines, and regulatory approvals. Aurika delays flagged; execution risk.
Risks the call surfaced
Corporate demand softness
MediumCorporate segment (target 55% of business) still muted despite geopolitical easing. IT hiring freezes and discretionary travel cuts offsetting leisure/MICE recovery. Analyst notes 'corporates slightly tepid to pick up.'
Execution risk on growth pipeline
HighAurika Nehru Place (610 rooms) delayed to CY31 from FY30 due to DDA tree-cutting approvals. Omaxe partnership (4,000 rooms) dependent on partner execution; 3-3.5 year timelines unproven. Fleur demerger CY27 contingent on NCLT approval.
Regulatory and compliance risk
Medium530 owned-hotel rooms deflagged in Q2 due to compliance gaps (Gurgaon lease termination, 450 rooms under review). SAR (Supplementary demands) and GST provisions creating 3.2% revenue headwind. Property tax demands from states pending.
Aurika brand positioning and unit economics
MediumAurika brand is new and unproven at scale. Aurika Mumbai selling at ₹8,900 ARR (analyst note: Marriott/luxury competitors at ₹25-30K). Aurika Nehru Place assumes ₹12,000 ARR start. Analyst skepticism: is Aurika a mid-market or luxury play?
Asset-light execution and partner dependency
MediumAsset-light model (Omaxe, franchisees) is bullish but shifts execution risk to partners. Fleur demerger pending; Omaxe partnership unproven; franchise fees dependent on partner RevPAR growth (not controlled).
Supply oversupply risk in key markets
LowLuxury segment seeing aggressive expansion by IHCL, ITC. Analyst (Prachi Agarwal) flagged 'supply outpacing demand, RevPAR growth model at risk.' Management counters: supply mostly Tier 2/3 (opportunity, not threat), and Lemon Tree is asset-light so can grow network without capital burden.
Management
Score 7/10. Transparent on challenges (deflagging, compliance, delays); candid on macro headwinds (corporate demand muted); specific on unit economics (Aurika ROCE, Fleur EBITDAR targets). Some evasion on H2 guidance ('difficult to explain'), but mostly forthcoming. Hit FY27 Q2 guidance (18% revenue, 90% PAT growth); maintained prior margin and capex targets; track record of delivery on annual guidance. Some delays (Aurika Nehru Place, Fleur demerger), but communicated transparently.
1 · Q3-Q4 FY27
Winter holiday season pickup; Diwali/festival demand recovery post-macro uncertainty
2 · FY28 (Apr 2027+)
Fleur Hotels Demerger listed; 2,500 rooms operationalized; merger synergy unlocked
3 · FY28-FY30
Omaxe partnership: 4,000 rooms across Tier 2/3 cities; fee-income leverage; no capex burden
Asset-light strategy is bullish, but unproven at scale.